Full text
PDFPage 204
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Behan P. O., Haniffah B. A. Gangliosides and neurological diseases. BMJ. 1992 Nov 28;305(6865):1309–1310. doi: 10.1136/bmj.305.6865.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bradley W. G. Critical review of gangliosides and thyrotropin-releasing hormone in peripheral neuromuscular diseases. Muscle Nerve. 1990 Sep;13(9):833–842. doi: 10.1002/mus.880130910. [DOI] [PubMed] [Google Scholar]
- Figueras A., Morales-Olivas F. J., Capellà D., Palop V., Laporte J. R. Bovine gangliosides and acute motor polyneuropathy. BMJ. 1992 Nov 28;305(6865):1330–1331. doi: 10.1136/bmj.305.6865.1330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schneider J. S., Pope A., Simpson K., Taggart J., Smith M. G., DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science. 1992 May 8;256(5058):843–846. doi: 10.1126/science.1350379. [DOI] [PubMed] [Google Scholar]
- Schneider J. S., Yuwiler A. GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism. Exp Neurol. 1989 Aug;105(2):177–183. doi: 10.1016/0014-4886(89)90117-9. [DOI] [PubMed] [Google Scholar]
- Skaper S. D., Leon A., Facci L. Ganglioside GM1 prevents death induced by excessive excitatory neurotransmission in cultured hippocampal pyramidal neurons. Neurosci Lett. 1991 May 13;126(1):98–101. doi: 10.1016/0304-3940(91)90381-3. [DOI] [PubMed] [Google Scholar]